Clinical Trials · NCT01132404
Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448
- Phase
- Phase 1/Phase 2
- Recruitment status
- Terminated
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Enrollment
- 9
- Start date
- Nov 2010
- Locations
- 1 site, France
- Primary endpoint
- For Phase 1 portion of study: to assess the safety and pharmacokinetics (PK) of TAK-448 in patients receiving a single dose of 1-month depot TAK-448